ARTICLE | Company News
Porphylix hematology news
May 14, 2012 7:00 AM UTC
Prophylix said PROFNAIT, a consortium led by the company, will receive a grant of up to €6 million ($7.8 million) from the European Commission's Framework Programme 7 (FP7) to develop Prophylix's human platelet antigen-1a (HPA-1a) immunoglobulin to prevent fetal and neonatal alloimmune thrombocytopenia (NAIT) due to HPA-1a incompatibility between mother and fetus. The consortium, which includes academic and commercial organizations from Norway, Sweden, Denmark and Germany, will secure sufficient plasma to manufacture the immunoglobulin and to conduct clinical development. ...